| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Treating rheumatoid arthritis to target: recommendations of an international task force.
|
Ann Rheum Dis
|
2010
|
10.97
|
|
2
|
Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study.
|
Arthritis Res Ther
|
2007
|
2.32
|
|
3
|
Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.
|
Arthritis Rheum
|
2003
|
2.16
|
|
4
|
Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis.
|
J Rheumatol
|
2010
|
2.11
|
|
5
|
Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes.
|
Arthritis Rheum
|
2004
|
2.01
|
|
6
|
Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes.
|
Arthritis Res Ther
|
2005
|
2.00
|
|
7
|
The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity.
|
J Rheumatol
|
2012
|
1.61
|
|
8
|
Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study.
|
J Rheumatol
|
2012
|
1.60
|
|
9
|
Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort.
|
J Rheumatol
|
2012
|
1.60
|
|
10
|
Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial.
|
Arthritis Care Res (Hoboken)
|
2013
|
1.57
|
|
11
|
Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
|
J Rheumatol
|
2015
|
1.50
|
|
12
|
Interstitial pneumonitis associated with infliximab therapy.
|
J Rheumatol
|
2006
|
1.49
|
|
13
|
Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review.
|
Rheumatology (Oxford)
|
2010
|
1.49
|
|
14
|
Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort.
|
J Rheumatol
|
2011
|
1.43
|
|
15
|
Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design.
|
J Rheumatol
|
2011
|
1.40
|
|
16
|
Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
|
J Rheumatol
|
2011
|
1.40
|
|
17
|
Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review.
|
J Rheumatol
|
2010
|
1.11
|
|
18
|
Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.
|
Ann Rheum Dis
|
2011
|
1.03
|
|
19
|
Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
|
Clin Exp Rheumatol
|
2011
|
1.03
|
|
20
|
Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
|
J Rheumatol
|
2004
|
1.02
|
|
21
|
Advantages and limitations of utility assessment methods in rheumatoid arthritis.
|
J Rheumatol
|
2007
|
0.94
|
|
22
|
Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis.
|
J Rheumatol
|
2012
|
0.92
|
|
23
|
Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis.
|
Arthritis Res Ther
|
2008
|
0.92
|
|
24
|
Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy.
|
J Rheumatol
|
2010
|
0.88
|
|
25
|
Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
|
Rheumatology (Oxford)
|
2012
|
0.88
|
|
26
|
Achieving remission in clinical practice: lessons from clinical trial data.
|
Clin Exp Rheumatol
|
2013
|
0.87
|
|
27
|
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
|
J Rheumatol
|
2012
|
0.87
|
|
28
|
Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.
|
J Rheumatol
|
2012
|
0.86
|
|
29
|
Cardiovascular adverse effects of anti-inflammatory drugs.
|
Antiinflamm Antiallergy Agents Med Chem
|
2013
|
0.86
|
|
30
|
Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study.
|
Curr Med Res Opin
|
2009
|
0.86
|
|
31
|
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.
|
Clin Rheumatol
|
2008
|
0.84
|
|
32
|
Validity of quality of life measurement tools--from generic to disease-specific.
|
J Rheumatol Suppl
|
2011
|
0.84
|
|
33
|
Biologics and the cardiovascular system: a double-edged sword.
|
Antiinflamm Antiallergy Agents Med Chem
|
2013
|
0.83
|
|
34
|
Care gap in patients with early inflammatory arthritis with a high fracture risk identified using FRAX(®).
|
J Rheumatol
|
2010
|
0.82
|
|
35
|
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.
|
Clin Rheumatol
|
2015
|
0.81
|
|
36
|
Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort.
|
Rheumatol Int
|
2012
|
0.81
|
|
37
|
Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
|
J Rheumatol
|
2011
|
0.81
|
|
38
|
Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
|
J Rheumatol
|
2013
|
0.81
|
|
39
|
Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort.
|
J Rheumatol
|
2013
|
0.81
|
|
40
|
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.
|
Semin Arthritis Rheum
|
2010
|
0.81
|
|
41
|
Subsequent entry biologics/biosimilars: a viewpoint from Canada.
|
Clin Rheumatol
|
2012
|
0.81
|
|
42
|
To switch or to change class-the biologic dilemma in rheumatoid arthritis.
|
Nat Rev Rheumatol
|
2010
|
0.80
|
|
43
|
Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.79
|
|
44
|
Important issues at heart: cardiovascular risk management in rheumatoid arthritis.
|
Ther Adv Musculoskelet Dis
|
2013
|
0.78
|
|
45
|
Etanercept in the treatment of rheumatoid arthritis.
|
Ther Clin Risk Manag
|
2007
|
0.78
|
|
46
|
Adalimumab therapy in rheumatoid arthritis.
|
Rheum Dis Clin North Am
|
2004
|
0.78
|
|
47
|
Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.
|
Clin Rheumatol
|
2009
|
0.78
|
|
48
|
Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.
|
Rheumatol Int
|
2013
|
0.78
|
|
49
|
Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases.
|
J Rheumatol Suppl
|
2010
|
0.78
|
|
50
|
Uncoupling of disease activity and structural damage. Does it matter clinically?
|
Ann Rheum Dis
|
2012
|
0.77
|
|
51
|
Reversible male infertility under treatment with an anti-TNFα agent: a case report.
|
Ann Rheum Dis
|
2011
|
0.76
|
|
52
|
Factors associated with time to diagnosis in early rheumatoid arthritis.
|
Rheumatol Int
|
2013
|
0.76
|
|
53
|
Preparing for subsequent entry biologics in dermatology and rheumatology in Canada.
|
J Cutan Med Surg
|
2013
|
0.75
|
|
54
|
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
|
Rheumatology (Oxford)
|
2015
|
0.75
|
|
55
|
Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
|
J Rheumatol
|
2009
|
0.75
|
|
56
|
Therapeutic targets for rheumatoid arthritis.
|
J Rheumatol Suppl
|
2009
|
0.75
|
|
57
|
Quality of life issues in pediatric immune-mediated inflammatory disease.
|
J Rheumatol Suppl
|
2011
|
0.75
|